ophthalmology

News

Immunovant's thyroid eye disease drug flunks pivotal trials

Immunovant shares were sliding today after it reported that FcRn blocker batoclimab failed a pair of phase 3 trials in thyroid eye disease.

News

Sanofi linked to takeover bid for Ocular Therapeutix

Sanofi is reported to be preparing a move to take control of US biotech Ocular Therapeutix, after an initial bid was rejected last year.

News

A woman hides her face behind her hands, revealing her right eye

Ocugen shares fall, despite positive eye disorder trial

A trial of Ocugen's gene therapy for sight-robbing disease geographic atrophy (GA) showed efficacy – but still sparked a selloff in its shares.

News

Belite plans filing for oral Stargardt drug after phase 3 wi...

The first therapy for sight-robbing Stargardt disease could be on the way, as Belite Bio's tinlarebant hits the mark in a phase 3 trial.

News

Joy as retinal implant restores sight in geographic atrophy

A wireless retinal implant already filed for approval has been shown to restore vision in patients with eye disease geographic atrophy.

News

Black and white close up image of an eye

Oculis takes second eye disease therapy into pivotal trials

Oculis is poised to start registration trials for privosegtor, its drug candidate for neuro-ophthalmic diseases, in the wake of positive phase 2 data.

Immunovant's thyroid eye disease drug flunks pivotal trials

Sanofi linked to takeover bid for Ocular Therapeutix

Ocugen shares fall, despite positive eye disorder trial

Belite plans filing for oral Stargardt drug after phase 3 wi...

Joy as retinal implant restores sight in geographic atrophy

Oculis takes second eye disease therapy into pivotal trials

Lundbeck preps for key bexicaserin data around year-end

Discover a new era of healthcare panel engagement: Grounded ...

ophthalmology

Editor's Picks